The analysis also breaks down how cash runway calculations determine survival probability after setbacks, plus the specific competitive landscape pressures from J&J's Talzenna and Pfizer's Xtandi that make market entry even harder: https://vianews.market/biotech-equities/kyntra-bio-faces-catastrophic-risk-as-fg-3246-oncology-trial-failure-looms